The correlation of NF-κB p65 in blood monocytes with the severity of inflammation in acute exacerbation chronic obstructive pulmonary disease with palmatine treatments

doi:10.3877/cma.j.issn.2095-655X.2019.04.012

Abstract

Abstract:

Objective

To explore the value of NF-κB p65 activation level blood monocytes on evaluation of the effects of palmatine treatment in acute exacerbation chronic obstructive pulmonary disease (AECOPD).

Methods

In this clinical study, 100 patients with moderate AECOPD in Respiratory Department of the People′s Hospital of Fengjie County from October 2017 to January 2019 were randomly divided into two groups, control group (regular treatment) and observation group (palmatine and regular treatment), with 50 patients in each group. Before and after 7 days administrations, blood gas indexes (PaO₂, PaCO₂, and pH) and lung functions (FEV₁% pred) were recorded, the serum levels of TNF-α and IL-8 were analyzed by ELISA, western blot was performed to measure phosph-NF-κB p65 and total NF-κB p65 in blood monocytes. Student′s t-test was obtained to analyze continuous variable between the two groups. Pearson correlation test was used to evaluate the correlation between the ratio of phosph-NF-κB p65/total NF-κB p65 and the serum levels of TNF-α and IL-8.

Results

After 7 days administration, the levels of pH, PaO₂ and FEV₁% pred [(7.42±1.87), (67.50±9.31)mmHg, (53.62±16.54)%] were higher than those before treatment [(7.16±2.31), (40.4±13.6)mmHg, (36.17±18.27)%], the levels of PaCO₂, TNF-α, IL-8 and the ratio of phosph-NF-κB p65/total NF-κB p65 [(43.12±8.67)mmHg, (81.76±23.43)ng/L, (225.87±89.12)ng/L, (0.47±0.09)] were lower than those in the control group [(69.17±12.11)mmHg, (267.34±33.23)ng/L, (617.34±127.63)ng/L, (0.96±0.07)], the differences were statistically significant (t=-0.24, -0.31, -0.05, 0.04, 15.61, 25.12, 2.53, all P<0.05). At the same time, the levels of pH, PaO₂ and FEV₁% pred in the observation group were higher than those in the control group [(7.31±1.51), (62.71±14.12)mmHg, (44.64±10.47)%], and the levels of PaCO₂, TNF-α, IL-8 and the ratio of phosph-NF-κB p65/total NF-κB p65 were lower than those in the control group [(53.64±10.25)mmHg, (114.82±25.96)ng/L, (362.65±106.97)ng/L, (0.68±0.11)], the differences between groups were statistically significant (t=-2.99, -3.07, -3.26, 4.62, 5.26, 7.27, 4.55, all P<0.05). In the observation group, the ratio of phosph-NF-κB p65/total NF-κB p65 was significantly positively correlated with the serum level of TNF-α (r=0.622, P<0.001) and IL-8 (r=0.571, P<0.001). No significant adverse reactions were found in the study period.

Conclusions

The activation level of NF-κB p65 in blood monocytes closely correlated with the inflammation level in patients with AECOPD. Palmatine is an effective and safe treatment for the patients with AECOPD possibly through inhibiting the activation of NF-κB p65 in the inflammatory cells.

Key words: Pulmonary disease, chronic obstructive, Palmatine, Respiratory function, NF-kappa B

Bin Li, Haiju Li, Wei Zhang. The correlation of NF-κB p65 in blood monocytes with the severity of inflammation in acute exacerbation chronic obstructive pulmonary disease with palmatine treatments[J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(04): 273-278.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2019.04.012

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I04/273

Figures/Tables 3

References 20

[1]	Vogelmeier CF, Criner GJ, Martinez FJ，et al.Global strategy for the diagnosis，management，and prevention of chronic obstructive lung disease 2017 report.GOLD executive summary [J]．Am J Respir Crit Care Med，2017，195(5):557-582.
[2]	Wang C, Xu J, Yang L，et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study)：a national cross-sectional study [J]．Lancet，2018，391(10131):1706-1717.
[3]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组．慢性阻塞性肺疾病诊治指南(2013年修订版) [J/CD]．中国医学前沿杂志(电子版)，2014，6(2):67-80.
[4]	慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组．慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版) [J]．国际呼吸杂志，2017，37 (14):1041-1057.
[5]	Garth J, Barnes JW, Krick S．Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases [J]．Int J Mol Sci，2018，19(11):E3402.
[6]	Xie S, Wang K, Zhang W，et al. Immunodeficiency in patients with acute exacerbation of chronic obstructive pulmonary disease [J]．Inflammation，2018，41(5):1582-1589.
[7]	Lee WC, Kim JK, Kang JW，et al.Palmatine attenuates D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice [J]．Food Chem Toxicol，2010，48(1):222-228.
[8]	Yan B, Wang D, Dong S，et al.Palmatine inhibits TRIF-dependent NF-κB pathway against inflammation induced by LPS in goat endometrial epithelial cells [J]．Int Immunopharmacol，2017(45):194-200.
[9]	Lee JW, Mase N, Yonezawa T，et al.Palmatine attenuates osteoclast differentiation and function through inhibition of receptor activator of nuclear factor-κb ligand expression in osteoblast cells [J]．Biol Pharm Bull，2010，33(10):1733-1739.
[10]	Zhu T, Wu XL, Zhang W，et al.Glucagon like peptide-1 (GLP-1) modulates OVA-Induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice [J]．Int J Mol Sci，2015，16(9):20195-20211.
[11]	Zhu T, Li C, Zhang X，et al.GLP-1 enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway [J]．Mediators Inflamm，2018(2018):3601454.
[12]	Zhu T, Zhang W, Wang DX, et al. Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor [J]．Chin Med J (Engl)，2012，125(8):1457-1464.
[13]	Zhu T, Wang D, Zhang W，et al.Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-κB [J]．PLoS One，2013，8(2):e56407.
[14]	郭凯，殷少军．慢性阻塞性肺疾病急性加重期相关生物标志物及其诊断意义[J/CD]．中华诊断学电子杂志，2015，3(2):133-137.
[15]	兰世萍，叶春燕，王导新，等．黄藤素辅助治疗对支气管哮喘急性发作期患者炎症状态和肺功能的影响[J]．西部医学，2015，27(4):496-498.
[16]	Lin TL, Chen WW, Ding ZR, et al. Correlations between serum amyloid A，C-reactive protein and clinical indices of patients with acutely exacerbated chronic obstructive pulmonary disease [J]．J Clin Lab Anal，2019，33(4):e22831.
[17]	Zhang J, Bai C．The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease [J]．Tanaffos，2018，17(1):13-21.
[18]	Mai CT, Wu MM, Wang CL, et al. Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation [J]．Mol Immunol，2019(105):76-85.
[19]	Hambright HG, Batth IS, Xie J，et al.Palmatine inhibits growth and invasion in prostate cancer cell：potential role for rpS6/NFκB/FLIP [J]．Mol Carcinog，2015，54(10):1227-34.
[20]	Liu YC, Hsiao YY, Ku KL，et al.Mahonia oiwakensis extract and its bioactive compounds exert anti-Inflammatory activities and VEGF production through M2-macrophagic polarization and STAT6 activation [J]．J Med Food，2018，21(7):654-664.

指标	对照组		t值	P值	观察组		t值	P值
指标	治疗前	治疗第7天后	t值	P值	治疗前	治疗第7天后	t值	P值
pH	7.18±2.92	7.31±1.51	－0.15	0.042	7.16±2.31^a	7.42±1.87^b	－0.24	0.015
PaO₂(mmHg)	39.34±11.25	62.71±14.12	－0.45	0.022	40.40±13.62^a	67.42±9.31^b	－0.31	0.035
PaCO₂(mmHg)	65.91±15.24	53.64±10.25	0.19	0.034	69.17±12.11^a	43.12±8.67^b	0.04	0.006
FEV₁% pred(%)	35.46±15.72	44.64±10.47	－0.18	0.004	36.23±18.27^a	53.62±16.54^b	－0.05	0.002

指标	对照组		t值	P值	观察组		t值	P值
指标	治疗前	治疗第7天后	t值	P值	治疗前	治疗第7天后	t值	P值
pH	7.18±2.92	7.31±1.51	－0.15	0.042	7.16±2.31^a	7.42±1.87^b	－0.24	0.015
PaO₂(mmHg)	39.34±11.25	62.71±14.12	－0.45	0.022	40.40±13.62^a	67.42±9.31^b	－0.31	0.035
PaCO₂(mmHg)	65.91±15.24	53.64±10.25	0.19	0.034	69.17±12.11^a	43.12±8.67^b	0.04	0.006
FEV₁% pred(%)	35.46±15.72	44.64±10.47	－0.18	0.004	36.23±18.27^a	53.62±16.54^b	－0.05	0.002

指标	对照组(n＝50)		t值	P值	观察组(n＝50)		t值	P值
指标	治疗前	治疗第7天后	t值	P值	治疗前	治疗第7天后	t值	P值
TNF-α	277.44±29.67	114.82±25.96	14.01	<0.001	267.34±33.23^a	81.76±23.41^b	15.61	<0.001
IL-8	588.97±131.42	362.65±106.97	21.23	<0.001	617.34±127.63^a	225.87±89.12^b	25.12	<0.001

指标	对照组(n＝50)		t值	P值	观察组(n＝50)		t值	P值
指标	治疗前	治疗第7天后	t值	P值	治疗前	治疗第7天后	t值	P值
TNF-α	277.44±29.67	114.82±25.96	14.01	<0.001	267.34±33.23^a	81.76±23.41^b	15.61	<0.001
IL-8	588.97±131.42	362.65±106.97	21.23	<0.001	617.34±127.63^a	225.87±89.12^b	25.12	<0.001

Please choose a citation manager

Content to export